Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 4Sarcoma, Myeloid 2Recurrence 2Leukemia, Monocytic, Acute 2Leukemia, Biphenotypic, Acute 2Leukemia 2Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Philadelphia Chromosome 1Myeloproliferative Disorders 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Down Syndrome 1Burkitt Lymphoma 1

Interventions

nilotinib 2asciminib 2Dasatinib 2Cyclophosphamide 2fludarabine 1bosutinib 1Vincristine 1Prednisone 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Imatinib Mesylate 1Etoposide 1Dexamethasone 1Daunorubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Philadelphia Chromosome × Mitoxantrone × 1 year × Clear all
NCT02523976 2026-02-11

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡